Alessa Therapeutics is developing localized drug-eluting implants for the sustained delivery of anti-androgen therapy directly to prostate tumors, minimizing systemic exposure. This approach targets prostate diseases, addressing the need for more effective and tolerable treatment options for patients with prostate cancer and benign prostate hyperplasia.
Funding
$21.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for prostate cancer and benign prostate hyperplasia often involve systemic therapies, leading to significant side effects due to exposure of healthy tissues to the drugs. Effective drug delivery directly to the prostate tumor while minimizing systemic exposure remains a challenge.
Solution
Alessa Therapeutics is developing localized drug-eluting implants designed for sustained delivery of anti-androgen therapy directly to prostate tumors. This approach aims to minimize systemic drug exposure, reducing the side effects associated with traditional treatments. The implants provide a minimally invasive method for delivering targeted therapy, potentially improving treatment outcomes and quality of life for patients with prostate diseases. Clinical studies are underway to evaluate the safety and efficacy of these implantable systems.
Target Audience
The primary target audience includes patients with prostate cancer and benign prostate hyperplasia, as well as oncologists and urologists seeking more effective and tolerable treatment options.
Features
- Localized drug delivery directly to the prostate tumor
- Sustained release of anti-androgen therapy
- Minimally invasive implantation procedure
- Reduced systemic drug exposure compared to traditional therapies
- Drug-eluting implant technology
- Clinical trials currently in progress (Enolen, Biolen + RT, Biolen-PC)